MedTrace Logo

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

NCT02473562 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-10-09

No results posted yet for this study

Summary

The effect of varenicline, an alpha4beta2 nicotinic receptor partial agonist on excessive daytime sleepiness in Parkinson's disease will be studied in a randomized, double blind, placebo-controlled clinical trial with a within-subject crossover design.

Conditions

Interventions

DRUG

Varenicline

Tablet 1 mg BID

DRUG

Placebo (for varenicline)

Tablet 1 mg BID

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Elisabeth Foncke, PhD, MD · VU University Medical Center, depart. of neurology

  • Bernard Uitdehaag, Phd, MD · VU University Medical Center, depart. of neurology

  • Tom van Mierlo, MD · VU University Medical Center, depart. of neurology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473562 on ClinicalTrials.gov